Inscription Capital’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$321K Buy
5,291
+54
+1% +$3.15K 0.03% 470
2025
Q4
$282K Sell
5,237
-3,485
-40% -$168K 0.03% 502
2025
Q3
$393K Buy
8,722
+1,576
+22% +$73.6K 0.04% 412
2025
Q2
$331K Sell
7,146
-2,934
-29% -$144K 0.05% 330
2025
Q1
$547K Buy
+10,080
New +$588K 0.09% 168
2024
Q3
$610K Sell
11,791
-554
-4% -$26K 0.09% 164
2024
Q2
$513K Buy
12,345
+2,265
+22% +$101K 0.08% 174
2024
Q1
$547K Buy
10,080
+3,920
+64% +$200K 0.09% 168
2023
Q4
$316K Buy
6,160
+860
+16% +$45.1K 0.09% 164
2023
Q3
$308K Buy
5,300
+74
+1% +$4.53K 0.1% 143
2023
Q2
$334K Sell
5,226
-115
-2% -$7.71K 0.1% 142
2023
Q1
$370K Buy
5,341
+545
+11% +$38.4K 0.1% 140
2022
Q4
$345K Hold
4,796
0.12% 146
2022
Q3
$341K Sell
4,796
-3,984
-45% -$289K 0.1% 139
2022
Q2
$676K Buy
8,780
+4,500
+105% +$343K 0.12% 122
2022
Q1
$315K Sell
4,280
-25
-0.6% -$1.68K 0.09% 155
2021
Q4
$268K Buy
4,305
+270
+7% +$15.8K 0.07% 187
2021
Q3
$241K Sell
4,035
-11,957
-75% -$787K 0.08% 189
2021
Q2
$1.07M Buy
15,992
+11,767
+279% +$767K 0.12% 125
2021
Q1
$269K Buy
4,225
+350
+9% +$21.8K 0.09% 159
2020
Q4
$242K Buy
3,875
+50
+1% +$3.07K 0.09% 156
2020
Q3
$231K Buy
+3,825
New +$230K 0.1% 149
2019
Q2
Sell
-350
Closed -$17K 119
2019
Q1
$17K Sell
350
-454
-56% -$22.6K 0.01% 225
2018
Q4
$42K Buy
+804
New +$43.2K 0.02% 202

Other funds holding BMY

Inscription Capital's BMY Position: Q1 2026 in Review

Inscription Capital increased its Bristol-Myers Squibb (BMY) stake by 1% in Q1 2026, buying an estimated $3.15K and bringing the position to 5,291 shares worth $321K. The position accounts for 0.03% of the portfolio, ranked #470.

Inscription Capital first reported a position in BMY in Q4 2018 and has held it in 24 quarters since. The position peaked at $1.07M in Q2 2021. 2,520 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • Inscription Capital held 5,291 shares of Bristol-Myers Squibb worth $321K as of Q1 2026.
  • Inscription Capital bought 54 Bristol-Myers Squibb shares in Q1 2026, an estimated $3.15K.
  • Bristol-Myers Squibb made up 0.03% of Inscription Capital's portfolio in Q1 2026, its #470 holding.
  • Inscription Capital first reported a position in Bristol-Myers Squibb in Q4 2018 and has held it in 24 quarters since.
  • Inscription Capital's Bristol-Myers Squibb position peaked at $1.07M in Q2 2021.
  • 2,520 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Inscription Capital's 13F filing for Q1 2026, filed 20 Apr 2026.